{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-127931","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.481536+00:00","generated_at":"2026-05-15T08:41:06.487941+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"MiNK Therapeutics confirms active discussions for combination trials and strategic investments","bullets":["Company is in active discussions with multiple parties for potential combination trials of agenT-797.","Discussions also include potential strategic minority investments in MiNK.","No binding arrangements have been publicly disclosed; no assurance of final agreements.","Clarification issued in response to third-party postings regarding potential trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-127931","json":"https://secwatch.observer/filing/0001193125-26-127931.json","markdown":"https://secwatch.observer/filing/0001193125-26-127931.md","text":"https://secwatch.observer/filing/0001193125-26-127931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526127931/0001193125-26-127931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526127931/inkt-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:41:06.487941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}